SCHEMBL1646753

SCHEMBL1646753

Cc1ccc(C2CCCCC2N)cc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR2A P28223 1/20 0.44
HTR2C P28335 1/20 0.44
HTR2B P41595 1/20 0.44
GRIA4 P48058 1/20 0.41
DPP4 P27487 1/20 0.41
KDM1A O60341 10/20 0.41
ALDH1A1 P00352 1/20 0.40
CYP1A2 P05177 1/20 0.40
CYP3A4 P08684 1/20 0.40
CYP2C9 P11712 1/20 0.40
CYP2C19 P33261 1/20 0.40
MAOB P27338 3/20 0.38
MAOA P21397 1/20 0.38
KCNH2 Q12809 2/20 0.38
RCOR1 Q9UKL0 2/20 0.38
SLC6A2 P23975 2/20 0.38
SLC6A4 P31645 2/20 0.38
SLC6A3 Q01959 2/20 0.38
KDM1B Q8NB78 1/20 0.38
SLC18A3 Q16572 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13763430 0.96 GRIA4 (0.45) HTR2AHTR2CHTR2BGRIA4DPP4
SCHEMBL734952 0.96 GRIA4 (0.45) HTR2AHTR2CHTR2BGRIA4DPP4
SCHEMBL12269936 0.96 GRIA4 (0.45) HTR2AHTR2CHTR2BGRIA4DPP4
SCHEMBL4260479 0.96 GRIA4 (0.45) HTR2AHTR2CHTR2BGRIA4DPP4
SCHEMBL4258361 0.79 HTR3A (0.46) HTR2AHTR2CHTR2BGRIA4KDM1A
SCHEMBL17892263 0.79 GRIA4 (0.41) HTR2CGRIA4KDM1ACYP1A2CYP3A4
SCHEMBL1644778 0.79 HTR3A (0.46) HTR2AHTR2CHTR2BGRIA4KDM1A
SCHEMBL4258364 0.79 HTR3A (0.46) HTR2AHTR2CHTR2BGRIA4KDM1A
SCHEMBL13598557 0.79 KDM1A (0.63) HTR2AHTR2CHTR2BKDM1AMAOB
SCHEMBL4257203 0.79 KDM1A (0.67) HTR2CKDM1AMAOBMAOASLC6A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-4666533-B2 2011-04-06 JP claimed
US-7411093-B2 Aminocycloalkanes as DPP-IV inhibitors HOFFMAN-LA ROCHE INC. (US) 2008-08-12 US claimed
JP-2008524279-A 2008-07-10 JP claimed
CN-101084184-A Cycloalkylamine derivative HOFFMANN LA ROCHE (CH) 2007-12-05 CN claimed
EP-1833782-A1 CYCLOALKYLAMINE DERIVATIVES F. Hoffmann-Roche AG (CH) 2007-09-19 EP claimed
WO-2006066770-A1 CYCLOALKYLAMINE DERIVATIVES F.HOFFMANN-LA ROCHE AG (CH) 2006-06-29 WO claimed
US-20060135512-A1 Aminocycloalkanes as DPP-IV inhibitors F. HOFFMANN-LA ROCHE AG (CH) 2006-06-22 US claimed
US-7411093-B2 Aminocycloalkanes as DPP-IV inhibitors HOFFMAN-LA ROCHE INC. (US) 2008-08-12 US disclosed
CN-101084184-A Cycloalkylamine derivative HOFFMANN LA ROCHE (CH) 2007-12-05 CN disclosed
EP-1833782-A1 CYCLOALKYLAMINE DERIVATIVES F. Hoffmann-Roche AG (CH) 2007-09-19 EP disclosed
WO-2006066770-A1 CYCLOALKYLAMINE DERIVATIVES F.HOFFMANN-LA ROCHE AG (CH) 2006-06-29 WO disclosed
US-20060135512-A1 Aminocycloalkanes as DPP-IV inhibitors F. HOFFMANN-LA ROCHE AG (CH) 2006-06-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060135512-A1 Aminocycloalkanes as DPP-IV inhibitors DPP4, DPP7, DPP3 HTR2A 1865/4885HTR2C 1770/4885HTR2B 1564/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.